Developer docs
API playgroundTry for free, no card

Search company profiles

ElmediX

Full company profile

uuid0003ppd

Namestring
ElmediX
Legal namestring
ElmediX NV
Websiteurl
elmedix.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

ElmediX is a Belgian medtech company developing a proprietary whole-body thermal therapy (hyperthermia) system as an adjunct cancer treatment. Founded in 2015 as a spin-off of the University of Antwerp by Prof. dr. John-Paul Bogers (CEO) and Ir. Johan Van den Bossche (Chairman), the company targets a core clinical problem: the limited treatment options for pancreatic cancer and other hard-to-treat metastatic cancers. The ElmediX device raises a patient's body temperature to 41.5°C in a controlled, stable manner using innovative temperature sensor technology, delivered under anesthesia in up to three sessions of 2–8 hours each. The mechanism is intended to enhance chemotherapy absorption, increase cancer cells' sensitivity to radiation (1.5–5x), activate the immune system, and directly induce tumor cell death through necrosis and apoptosis.

The technology platform is anchored by 8 patent families granted in the EU, USA, China, and Hong Kong, supplemented by registered ElmediX® trademarks in the same jurisdictions. Beyond the core therapeutic device, ElmediX has launched research tools: a Precision Egg Incubator (2023) for in-ovo tumor studies and a Phantom Thermal Simulator (2024) for human-body-mimicking research and training, both deployed at research institutions in Belgium, France, and Italy. The company operates from Leuven and Mechelen in Belgium and a New York office, supporting a planned US market entry.

ElmediX is pre-commercial: revenue is not publicly disclosed, pricing is not listed, and there are no paying commercial customers. The intended business model combines future hardware sales of the thermal therapy device to hospitals and oncology centers, treatment services delivered through partner institutions, and potential licensing of patented technology. GTM is enterprise-field-sales oriented, targeting oncologists, hospitals, and cancer treatment centers rather than direct-to-consumer channels. The company successfully completed its MATTERS First-In-Human clinical trial in 2025 and is planning the MATTERS-2 multicenter efficacy trial for 2026, positioning it for the next stage of clinical evidence generation and eventual commercialization.

Short descriptiontext

ElmediX is a Belgian medtech company developing whole-body thermal therapy at 41.5°C as an adjunct cancer treatment, primarily targeting pancreatic cancer. Founded in 2015 as a University of Antwerp spin-off, it serves healthcare providers and hospitals through its proprietary medical device.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMechelen, Belgium
HQ citystring
Mechelen
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
whole-body hyperthermia, thermal cancer therapy, pancreatic cancer treatment, medical device oncology, clinical thermal therapy
Industry1 code
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cancer Treatment Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Future commercialization of thermal therapy medical devices to hospitals and healthcare facilities. The company is developing a treatment device that will be sold to healthcare institutions.

elmedix.com
2Clinical Treatment Services
TypeProfessional Services
Description

Treatment delivery services through partnered hospitals and oncology centers where the thermal therapy is administered to patients.

elmedix.com
3Technology Licensing
TypeLicensing Royalties
Description

Potential licensing of patented thermal therapy technology to other medical device companies or healthcare institutions.

elmedix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ElmediX develops and is commercializing a proprietary whole-body thermal therapy medical device that raises a patient's body temperature to 41.5°C in a controlled manner as an adjunct anti-cancer treatment. The therapy is administered in up to 3 sessions of 2-8 hours each under anesthesia, enhancing the efficacy of chemotherapy and radiotherapy and stimulating immune response. The product is targeted at hospitals, oncology centers, and healthcare providers for treating cancer patients, primarily those with pancreatic cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Progression-free survival increased from 4.9 to 8.8 months with thermal therapy added to chemoradiotherapy (Ohguri et al, 2008)
+3 more records
Product overview1 text field

ElmediX is a medtech company offering a thermal therapy treatment system for cancer patients. The core product is the Thermal Therapy (Whole-Body Thermal Treatment) system, which raises body temperature to 41.5°C using a proprietary medical device with innovative temperature sensor technology. This is complemented by research tools including the Phantom Thermal Simulator (human body-mimicking phantom for training) and Precision Egg Incubator (for in-ovo research). The treatment is designed as an adjunct to chemotherapy and radiotherapy, enhancing their effectiveness by stimulating the immune system, directly killing cancer cells, and increasing drug absorption. The company completed its First-In-Human MATTERS clinical trial in 2025 and is planning the multi-center MATTERS-2 efficacy trial.

Product and service1 record
1Thermal Therapy (Whole-Body Thermal Treatment)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Pyrexar Medical (formerly BSD Medical)
TypeDirect peer
Description

A US-based hyperthermia device manufacturer offering systems for localized, regional, and whole-body hyperthermia used adjunctively with chemotherapy and radiation. Pyrexar is the closest direct peer to ElmediX, competing in the same oncology hyperthermia niche.

TypeDirect peer
Description

A German medical technology company specializing in whole-body and localized hyperthermia systems for cancer treatment. Celsius42 competes directly with ElmediX in the European oncology hyperthermia market.

TypeDirect peer
Description

A Hungarian company developing and commercializing oncological hyperthermia devices (modulated electro-hyperthermia) used in combination with conventional cancer therapies. Oncotherm is a direct peer in the cancer hyperthermia equipment category.

4Med-Logix
TypeDirect peer
Description

A European distributor and developer of hyperthermia systems used in oncology treatment. Med-Logix is comparable as a channel and equipment player in the same cancer hyperthermia category as ElmediX.

TypeDirect peer
Description

A Spanish medical technology company providing hyperthermia devices for cancer treatment in European and Latin American markets. Andromedic is comparable as a regional peer offering whole-body and localized hyperthermia equipment.

TypeBroad incumbent
Description

A global leader in radiation oncology equipment and software, now part of Siemens Healthineers. Varian is comparable as a broad incumbent serving the same oncology customer base that ElmediX targets, with thermal therapy positioned as complementary to its radiotherapy portfolio.

TypeBroad incumbent
Description

A Swedish-based global provider of radiation therapy, radiosurgery, and related oncology equipment and software. Elekta is a broad incumbent peer because its linear accelerators and brachytherapy systems are used by the same hospitals that would adopt ElmediX's adjunctive thermal therapy.

TypeBroad incumbent
Description

A US-based radiation oncology equipment company (CyberKnife, TomoTherapy). Accuray serves the same radiation oncology customers that ElmediX targets and represents a potential strategic partner or competitor depending on how thermal adjunctive therapy is positioned.

TypeEmerging player
Description

A US-based medical device company developing MR-guided radiation therapy systems. ViewRay is comparable as an emerging oncology technology player targeting similar hospital customers with novel, integrated treatment modalities.

TypeDirect peer
Description

A German medical technology company developing NanoTherm therapy, a minimally invasive, focal tumor ablation technique using magnetic nanoparticles. MagForce is comparable as a European medtech peer pursuing novel physics-based cancer therapies, including glioblastoma, with a similar clinical-development-stage profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ElmediX

Cancer Treatment Medical Deviceselmedix.com

ElmediX is a Belgian medtech company developing whole-body thermal therapy at 41.5°C as an adjunct cancer treatment, primarily targeting pancreatic cancer. Founded in 2015 as a University of Antwerp spin-off, it serves healthcare providers and hospitals through its proprietary medical device.

What ElmediX does

ElmediX is a Belgian medtech company developing a proprietary whole-body thermal therapy (hyperthermia) system as an adjunct cancer treatment. Founded in 2015 as a spin-off of the University of Antwerp by Prof. dr. John-Paul Bogers (CEO) and Ir. Johan Van den Bossche (Chairman), the company targets a core clinical problem: the limited treatment options for pancreatic cancer and other hard-to-treat metastatic cancers. The ElmediX device raises a patient's body temperature to 41.5°C in a controlled, stable manner using innovative temperature sensor technology, delivered under anesthesia in up to three sessions of 2–8 hours each. The mechanism is intended to enhance chemotherapy absorption, increase cancer cells' sensitivity to radiation (1.5–5x), activate the immune system, and directly induce tumor cell death through necrosis and apoptosis.

The technology platform is anchored by 8 patent families granted in the EU, USA, China, and Hong Kong, supplemented by registered ElmediX® trademarks in the same jurisdictions. Beyond the core therapeutic device, ElmediX has launched research tools: a Precision Egg Incubator (2023) for in-ovo tumor studies and a Phantom Thermal Simulator (2024) for human-body-mimicking research and training, both deployed at research institutions in Belgium, France, and Italy. The company operates from Leuven and Mechelen in Belgium and a New York office, supporting a planned US market entry.

ElmediX is pre-commercial: revenue is not publicly disclosed, pricing is not listed, and there are no paying commercial customers. The intended business model combines future hardware sales of the thermal therapy device to hospitals and oncology centers, treatment services delivered through partner institutions, and potential licensing of patented technology. GTM is enterprise-field-sales oriented, targeting oncologists, hospitals, and cancer treatment centers rather than direct-to-consumer channels. The company successfully completed its MATTERS First-In-Human clinical trial in 2025 and is planning the MATTERS-2 multicenter efficacy trial for 2026, positioning it for the next stage of clinical evidence generation and eventual commercialization.

ElmediX firmographics

Firmographics
Name
ElmediX
Legal name
ElmediX NV
Website
https://elmedix.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
ElmediX is a Belgian medtech company developing whole-body thermal therapy at 41.5°C as an adjunct cancer treatment, primarily targeting pancreatic cancer. Founded in 2015 as a University of Antwerp spin-off, it serves healthcare providers and hospitals through its proprietary medical device.
Ownership category
akta.pro rank

ElmediX industry classification

Industry
Product category
Cancer Treatment Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Whole-body hyperthermia
  • Thermal cancer therapy
  • Pancreatic cancer treatment
  • Medical device oncology
  • Clinical thermal therapy

Where ElmediX is headquartered

Location

Headquarters

HQ city
Mechelen
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

ElmediX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: Future commercialization of thermal therapy medical devices to hospitals and healthcare facilities. The company is developing a treatment device that will be sold to healthcare institutions.
  2. Clinical Treatment Services: Treatment delivery services through partnered hospitals and oncology centers where the thermal therapy is administered to patients.
  3. Technology Licensing: Potential licensing of patented thermal therapy technology to other medical device companies or healthcare institutions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

ElmediX product offering

Product offering

Core offering

ElmediX develops and is commercializing a proprietary whole-body thermal therapy medical device that raises a patient's body temperature to 41.5°C in a controlled manner as an adjunct anti-cancer treatment. The therapy is administered in up to 3 sessions of 2-8 hours each under anesthesia, enhancing the efficacy of chemotherapy and radiotherapy and stimulating immune response. The product is targeted at hospitals, oncology centers, and healthcare providers for treating cancer patients, primarily those with pancreatic cancer.

Product overview

ElmediX is a medtech company offering a thermal therapy treatment system for cancer patients. The core product is the Thermal Therapy (Whole-Body Thermal Treatment) system, which raises body temperature to 41.5°C using a proprietary medical device with innovative temperature sensor technology. This is complemented by research tools including the Phantom Thermal Simulator (human body-mimicking phantom for training) and Precision Egg Incubator (for in-ovo research). The treatment is designed as an adjunct to chemotherapy and radiotherapy, enhancing their effectiveness by stimulating the immune system, directly killing cancer cells, and increasing drug absorption. The company completed its First-In-Human MATTERS clinical trial in 2025 and is planning the multi-center MATTERS-2 efficacy trial.

Differentiator

Problem solved

Functional benefit

Products and services

  • Thermal Therapy (Whole-Body Thermal Treatment)

Quantifiable outcome

  • Progression-free survival increased from 4.9 to 8.8 months with thermal therapy added to chemoradiotherapy (Ohguri et al, 2008)
  • +3 more outcomes

Companies that use ElmediX

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

ElmediX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ElmediX partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

ElmediX competitors and assessment

Company assessment

Direct peers

  • Pyrexar Medical (formerly BSD Medical): A US-based hyperthermia device manufacturer offering systems for localized, regional, and whole-body hyperthermia used adjunctively with chemotherapy and radiation. Pyrexar is the closest direct peer to ElmediX, competing in the same oncology hyperthermia niche.
  • Celsius42 GmbH: A German medical technology company specializing in whole-body and localized hyperthermia systems for cancer treatment. Celsius42 competes directly with ElmediX in the European oncology hyperthermia market.
  • Oncotherm: A Hungarian company developing and commercializing oncological hyperthermia devices (modulated electro-hyperthermia) used in combination with conventional cancer therapies. Oncotherm is a direct peer in the cancer hyperthermia equipment category.
  • Med-Logix: A European distributor and developer of hyperthermia systems used in oncology treatment. Med-Logix is comparable as a channel and equipment player in the same cancer hyperthermia category as ElmediX.
  • Andromedic: A Spanish medical technology company providing hyperthermia devices for cancer treatment in European and Latin American markets. Andromedic is comparable as a regional peer offering whole-body and localized hyperthermia equipment.
  • MagForce: A German medical technology company developing NanoTherm therapy, a minimally invasive, focal tumor ablation technique using magnetic nanoparticles. MagForce is comparable as a European medtech peer pursuing novel physics-based cancer therapies, including glioblastoma, with a similar clinical-development-stage profile.

Broad incumbents

  • Varian Medical Systems (Siemens Healthineers): A global leader in radiation oncology equipment and software, now part of Siemens Healthineers. Varian is comparable as a broad incumbent serving the same oncology customer base that ElmediX targets, with thermal therapy positioned as complementary to its radiotherapy portfolio.
  • Elekta: A Swedish-based global provider of radiation therapy, radiosurgery, and related oncology equipment and software. Elekta is a broad incumbent peer because its linear accelerators and brachytherapy systems are used by the same hospitals that would adopt ElmediX's adjunctive thermal therapy.
  • Accuray: A US-based radiation oncology equipment company (CyberKnife, TomoTherapy). Accuray serves the same radiation oncology customers that ElmediX targets and represents a potential strategic partner or competitor depending on how thermal adjunctive therapy is positioned.

Emerging players

  • ViewRay: A US-based medical device company developing MR-guided radiation therapy systems. ViewRay is comparable as an emerging oncology technology player targeting similar hospital customers with novel, integrated treatment modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

ElmediX social profiles

Digital presence

ElmediX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ElmediX leadership team

Management profile

Number of profiles

Profiles5 records

ElmediX funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ElmediX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ElmediX

What does ElmediX do?

ElmediX develops and is commercializing a proprietary whole-body thermal therapy medical device that raises a patient's body temperature to 41.5°C in a controlled manner as an adjunct anti-cancer treatment. The therapy is administered in up to 3 sessions of 2-8 hours each under anesthesia, enhancing the efficacy of chemotherapy and radiotherapy and stimulating immune response. The product is targeted at hospitals, oncology centers, and healthcare providers for treating cancer patients, primarily those with pancreatic cancer.

Is ElmediX a public or private company?

ElmediX is a private company. It is classified as venture growth investor backed and is currently operating.

When was ElmediX founded?

ElmediX was founded in 2015. It employs 11 to 50 people.

Where is ElmediX based?

ElmediX is headquartered in Mechelen, Belgium, in the Europe region.

How does ElmediX make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Treatment Services and technology Licensing.

Who are ElmediX's main competitors?

Direct peers on record are Pyrexar Medical (formerly BSD Medical), Celsius42 GmbH, Oncotherm, Med-Logix, Andromedic and MagForce. Broad incumbents are Varian Medical Systems (Siemens Healthineers), Elekta and Accuray. ViewRay is listed as an emerging player.

Does ElmediX have an API?

No public API is recorded for ElmediX.

What industry is ElmediX in?

ElmediX's product category is Cancer Treatment Medical Devices. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals